Zacks Investment Research cut shares of CytomX Therapeutics (NASDAQ:CTMX) from a hold rating to a sell rating in a report released on Monday.
According to Zacks, “CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California. “
A number of other analysts have also recently commented on CTMX. Cantor Fitzgerald started coverage on shares of CytomX Therapeutics in a research report on Monday, October 23rd. They set an overweight rating and a $35.00 price target on the stock. ValuEngine cut shares of CytomX Therapeutics from a hold rating to a sell rating in a research report on Friday, December 1st. BidaskClub cut shares of CytomX Therapeutics from a buy rating to a hold rating in a research report on Thursday, December 7th. Finally, Citigroup started coverage on shares of CytomX Therapeutics in a research report on Friday, January 5th. They set a buy rating and a $40.00 price target on the stock. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of $32.78.
Shares of CytomX Therapeutics (NASDAQ CTMX) opened at $27.85 on Monday. The firm has a market capitalization of $1,070.00 and a price-to-earnings ratio of -17.74. CytomX Therapeutics has a 1-year low of $11.44 and a 1-year high of $29.04.
In other news, Director Frederick W. Gluck sold 10,000 shares of the stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $25.01, for a total transaction of $250,100.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Debanjan Ray sold 2,500 shares of the stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $20.58, for a total transaction of $51,450.00. The disclosure for this sale can be found here. Insiders have sold 56,466 shares of company stock worth $1,267,014 in the last ninety days. Insiders own 8.00% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in the company. Nationwide Fund Advisors boosted its position in shares of CytomX Therapeutics by 39.4% during the 2nd quarter. Nationwide Fund Advisors now owns 16,365 shares of the biotechnology company’s stock worth $254,000 after purchasing an additional 4,622 shares in the last quarter. Iguana Healthcare Management LLC boosted its position in shares of CytomX Therapeutics by 7.1% during the 4th quarter. Iguana Healthcare Management LLC now owns 75,000 shares of the biotechnology company’s stock worth $1,583,000 after purchasing an additional 5,000 shares in the last quarter. Algert Global LLC boosted its position in shares of CytomX Therapeutics by 11.7% during the 4th quarter. Algert Global LLC now owns 51,233 shares of the biotechnology company’s stock worth $1,082,000 after purchasing an additional 5,380 shares in the last quarter. New York State Common Retirement Fund boosted its position in shares of CytomX Therapeutics by 18.6% during the 3rd quarter. New York State Common Retirement Fund now owns 36,900 shares of the biotechnology company’s stock worth $670,000 after purchasing an additional 5,800 shares in the last quarter. Finally, Bank of Montreal Can bought a new position in shares of CytomX Therapeutics during the 4th quarter worth about $124,000. 75.31% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “CytomX Therapeutics (CTMX) Downgraded by Zacks Investment Research” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another publication, it was copied illegally and republished in violation of international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/20/cytomx-therapeutics-ctmx-downgraded-by-zacks-investment-research.html.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Get a free copy of the Zacks research report on CytomX Therapeutics (CTMX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.